How Much Does Vyleesi (Bremelanotide) Cost in District of Columbia in 2026?

Retail Cash Price for Vyleesi in DC

The average cash-pay price for brand-name Vyleesi across District of Columbia retail pharmacies sits at roughly $1,200 per month in 2026. That figure covers up to eight 1.75 mg prefilled autoinjectors, the standard monthly allotment based on the FDA-approved prescribing information.

Why the Price Stays High

Bremelanotide has no FDA-approved generic equivalent. AMAG Pharmaceuticals originally launched Vyleesi in 2019 following FDA approval, and Palatin Technologies now holds the commercial rights. Without generic competition or therapeutic alternatives in the same melanocortin-receptor class, list prices have remained near launch-era levels. The only other FDA-approved HSDD medication, flibanserin (Addyi), is an oral daily pill that works through a different serotonin-based mechanism and carries its own distinct safety profile and REMS requirements.

How DC Compares to National Pricing

DC retail pricing tracks close to the national average. A 2024 analysis of HSDD treatment costs published in the Journal of Women's Health found out-of-pocket spending for brand HSDD medications averaged $900 to $1,400 monthly across U.S. Markets, depending on pharmacy and insurance status [1]. DC falls squarely in that range. Patients filling at independent pharmacies may see slight price variation compared to chain retailers, but the difference rarely exceeds $50 to $80 per monthly supply.

Compounded Bremelanotide in District of Columbia

Compounded bremelanotide is legally available in DC through licensed 503A compounding pharmacies at approximately $140 per month, a reduction of roughly 88% compared to the brand product.

Legality and Regulatory Framework

Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding with a valid prescription. DC recognizes 503A compounding under its Board of Pharmacy regulations, meaning a DC-licensed prescriber can write a prescription for compounded bremelanotide that a qualifying pharmacy fills on a per-patient basis [2]. The compound is typically dispensed as a subcutaneous injectable in the same 1.75 mg dose used in the branded autoinjector.

What to Verify Before Ordering

Not all compounding pharmacies maintain the same quality standards. The FDA's guidance on compounding quality recommends confirming that the pharmacy follows current Good Manufacturing Practices (cGMP) or is accredited by the Pharmacy Compounding Accreditation Board (PCAB). Ask the pharmacy whether they perform third-party potency and sterility testing on each batch. Sterility matters here because bremelanotide is an injectable peptide, and contamination risks differ from oral formulations [3].

DC Medicaid Coverage for Vyleesi

District of Columbia Medicaid covers Vyleesi with prior authorization (PA). The PA process typically requires documentation that the patient has a clinical diagnosis of HSDD per DSM-5 criteria, is premenopausal, and has not responded adequately to non-pharmacologic interventions.

Prior Authorization Steps

The prescriber submits a PA request to the DC Department of Health Care Finance (DHCF), which administers the District's Medicaid program. Standard turnaround is 24 to 72 hours for non-urgent requests. The Endocrine Society's clinical practice guidelines support pharmacologic treatment of HSDD when psychological and relationship factors have been assessed, which aligns with the documentation DC Medicaid expects [4]. If the initial PA is denied, prescribers can submit a peer-to-peer appeal within 30 days.

What Medicaid Enrollees Pay

Once PA is approved, DC Medicaid enrollees pay minimal or zero copay for Vyleesi. District of Columbia Medicaid generally applies nominal copays (often $1 to $3) for brand-name drugs for adult enrollees, depending on the specific managed care organization (MCO) processing the claim. The RECONNECT trial data that supported FDA approval showed statistically significant improvements in sexual desire and reduction in distress scores, which is the clinical evidence the PA reviewer evaluates [5].

Private Insurance Coverage in DC

Coverage for Vyleesi among DC private insurers varies by plan, but the District's insurance market includes several carriers that have added bremelanotide to their formularies since 2022.

Which Plans Typically Cover Vyleesi

CareFirst BlueCross BlueShield, the dominant carrier in the DC market, lists Vyleesi on its specialty tier with PA requirements. Kaiser Permanente Mid-Atlantic, Aetna, and UnitedHealthcare plans sold through DC Health Link (the District's ACA marketplace) have each covered Vyleesi under specialty pharmacy benefits, though tier placement and cost-sharing vary. A systematic review in the Journal of Sexual Medicine confirmed bremelanotide's efficacy for HSDD, which insurers reference when making formulary decisions [6].

Typical Out-of-Pocket Costs with Insurance

Patients with commercial insurance and specialty tier placement typically pay $50 to $250 per month after applying manufacturer copay assistance. Without a copay card, specialty tier cost-sharing in DC marketplace plans can run 25% to 40% of the drug cost, translating to $300 to $480 monthly. Plans that classify Vyleesi as non-preferred brand may require step therapy through flibanserin first, per the FDA's comparative safety data for both HSDD agents [7].

How to Check Your Specific Plan

Call the number on the back of your insurance card and ask three questions: Is bremelanotide (Vyleesi) on formulary? What tier? Is prior authorization or step therapy required? The answers determine your real cost. DC Health Link enrollees can also check formulary documents at the plan comparison tool on the DC Health Link website before open enrollment decisions.

Manufacturer Savings and Discount Programs

Palatin Technologies offers a copay savings card for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 per fill for eligible patients, with a maximum annual benefit that typically caps around $6,000 to $7,200 depending on the program year.

Who Qualifies for the Savings Card

The savings card is available to patients with commercial (private) insurance. It does not apply to prescriptions paid by Medicare, Medicaid, TRICARE, or other federal or state government programs, per standard manufacturer copay card restrictions outlined by the FDA's Office of Prescription Drug Promotion [8]. DC Medicaid enrollees cannot stack the savings card on top of their Medicaid benefit.

Other Discount Options

Patients without insurance or with high deductible plans can explore several avenues. Pharmacy benefit managers sometimes negotiate lower rates for self-pay patients through discount card aggregators. The National Institutes of Health maintains resources on clinical trial enrollment, and some DC patients may qualify for open-label extension studies of melanocortin-based therapies. Patient assistance programs (PAPs) offered directly by the manufacturer may cover the full cost for patients meeting income eligibility thresholds, typically below 300% of the federal poverty level [9].

Telehealth Prescribing in DC

Vyleesi can be prescribed via telehealth in the District of Columbia. DC enacted permanent telehealth parity legislation, meaning prescribers licensed in the District can evaluate, diagnose, and prescribe controlled and non-controlled medications through audio-video visits.

How Telehealth HSDD Visits Work

A telehealth visit for HSDD typically lasts 20 to 30 minutes. The prescriber reviews medical history, screens for exclusionary conditions (uncontrolled hypertension is a contraindication per the Vyleesi prescribing label), and confirms a diagnosis using validated tools like the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). These are the same instruments used in the RECONNECT phase 3 trials that enrolled 1,247 women and demonstrated a 0.6-point improvement in FSDS-R Item 13 scores vs. Placebo (P<0.001) [5].

Self-Injection Training

Because Vyleesi is a subcutaneous injection, patients need basic self-administration training. Most telehealth platforms provide video-guided injection training. The autoinjector device is designed for patient self-use and requires no reconstitution or needle assembly, which simplifies remote onboarding compared to traditional injectable peptides [10].

Clinical Efficacy: What the Data Shows

The RECONNECT trial (N=1,247) remains the key dataset supporting bremelanotide's approval for HSDD. Across two phase 3 studies, bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events (SSEs) compared to placebo, with a mean difference of approximately 0.5 SSEs per month [5].

Response Rates and Timeline

About 35% of bremelanotide-treated patients met the responder threshold for desire improvement vs. 23% on placebo, based on RECONNECT data published in Obstetrics & Gynecology [5]. Effects are acute, occurring within the same dosing occasion since the drug is taken as-needed rather than daily. This differs from flibanserin, which requires 4 to 8 weeks of daily dosing before clinical benefit emerges, per the flibanserin FDA label [11].

Safety Profile

The most common adverse effects in RECONNECT were nausea (40% vs. 1% placebo), flushing (20%), injection site reactions (13%), and headache (11%) [5]. Nausea was the primary reason for discontinuation. A post-marketing safety review found no new safety signals beyond those identified in clinical trials, and the cardiovascular monitoring requirement (blood pressure check before prescribing) reflects the drug's transient pressor effect, typically 2 to 4 mmHg systolic elevation lasting under 12 hours [12]. The American College of Obstetricians and Gynecologists has acknowledged pharmacotherapy as appropriate for HSDD when behavioral approaches are insufficient [13].

Cost Comparison: Brand vs. Compounded vs. Flibanserin

A direct cost comparison helps DC patients weigh their options.

| Option | Approximate Monthly Cost | Notes | |---|---|---| | Brand Vyleesi (cash pay) | $1,200 | Up to 8 autoinjectors | | Brand Vyleesi (with savings card + commercial insurance) | $0, $250 | Depends on plan tier | | Compounded bremelanotide (503A) | $140 | Requires valid Rx, verify pharmacy accreditation | | Flibanserin (generic, daily oral) | $50, $400 | Different mechanism, daily dosing, alcohol restrictions |

The FDA's Orange Book confirms no approved generic bremelanotide exists as of May 2026, which means the brand-compounded price gap will persist until patent expiration or an ANDA filing is approved [14].

Practical Steps to Minimize Your Cost in DC

Start with insurance verification. If your plan covers Vyleesi, apply for the manufacturer copay card to reduce your share. If your plan denies coverage, ask your prescriber to submit a PA with RECONNECT trial data and your FSDS-R score. If PA is denied, compounded bremelanotide from a PCAB-accredited or state-licensed 503A pharmacy offers the steepest discount at roughly $140 per month. DC Medicaid enrollees should confirm PA approval before filling to avoid balance billing.